With Regeneron poised to announce a drug pricing deal with the White House Thursday, all 17 companies targeted in a round of ...

The FDA has doled out two manufacturing-related complete response letters (CRLs), slamming the brakes on prospective ...

Daiichi Sankyo has postponed its annual report by two weeks to allow for additional time to finalize the financial figures. | ...

During Pfizer's right-sizing push after the COVID-19 pandemic, the company's multibillion-dollar cost-cutting campaign has ...

After a series of regulatory and clinical setbacks for Sanofi’s tolebrutinib, the French pharma has scored a victory for the ...

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift ...

In a brutal first quarter for Roche, key drugs in the company’s pharmaceutical division fall short of Wall Street ...

Travis Smith was a very serious baby. Born completely unable to hear, his mother, Sierra, struggled to see his personality ...

Merck & Co. unveiled the much-anticipated first look at its PD-1xVEGF bispecific data. China's Zai Lab is looking to go ...

As pharma giants slash headcounts and routinely strike billion-dollar M&A deals, another trend is steadily playing out at many of the largest drugmakers: the adoption of AI on a corporate scale. Count ...

An established sales force and payer authorization criteria will fuel a fast launch for Travere Therapeutics’ Filspari in its ...

Normally on Big Pharma earnings calls, execs are eager to talk up their new launches and tout blockbuster expectations. | In ...